



YOUR PATIENTS TRUST YOU

WHAT YOU SAY MATTERS—Be confident so they can feel confident saying yes.

Your recommendation is the strongest predictor of patients getting vaccinated.¹

1 SHINGLES: PAINFUL AND DISRUPTIVE

Shingles is a blistering rash that can be **excruciatingly painful**, usually lasting 7 to 10 days, and can disrupt everyday activities such as work, family time, and sleep.²⁻⁴

2 RISK: AGE AND COMORBIDITIES

Shingles risk **sharply increases starting at 50 years old**.²
Certain chronic conditions can also increase the risk of shingles.⁵

3 SHINGRIX: OUTSTANDING EFFICACY

SHINGRIX, administered as a 2-dose series, was **proven more than 90% effective in preventing shingles** in people 50 years and older.^{6,*}
The most common side effects are pain, redness, and swelling at the injection site, muscle pain, tiredness, headache, shivering, fever, and upset stomach.

*Data from the phase 3 ZOE-50 (≥50 years old) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years old from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.^{6,7}

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

Please see additional Important Safety Information for SHINGRIX throughout and full Prescribing Information, also available at [SHINGRIXHCP.com](https://www.shingrixhcp.com).

IDENTIFY YOUR PATIENTS AT INCREASED RISK OF SHINGLES

- **99.5%** of people ≥ 50 years old are infected with the **VARICELLA ZOSTER VIRUS**^{2,8}
- In **1** in **3** people, the dormant virus reactivates in their lifetime and causes shingles²
- Starting at **50 YEARS OLD**, shingles risk **SHARPLY INCREASES**²
- Additional risk factors for shingles⁵:
DIABETES, ASTHMA, COPD, CHRONIC KIDNEY DISEASE, CARDIOVASCULAR CONDITIONS*

*Cardiovascular conditions include heart disease, heart failure, hypertension, hyperlipidemia, stroke, atrial fibrillation/flutter, and other cardiovascular disease.

COPD=chronic obstructive pulmonary disease.

ADMINISTER OR SCHEDULE TODAY.

Recommend SHINGRIX.



Scan the QR code or visit ScheduleSHINGRIX.com.

Important Safety Information (cont'd)

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)

Please see additional Important Safety Information for SHINGRIX throughout and full Prescribing Information, also available at SHINGRIXHCP.com.



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)



SHINGRIX IS **\$0** FOR MOST PATIENTS ≥ 50 YEARS OLD^{9,10,*}

- **98%** of commercial patients pay **\$0 for SHINGRIX**^{9,†}
- Medicare Part D patients can get **SHINGRIX for \$0** through their pharmacy¹⁰

*Coverage and cost may vary and are subject to change without notice.
Reimbursement decisions are made by individual insurance plans.

†Source: Based on IQVIA data of paid 2023 SHINGRIX claims.

HELP YOUR PATIENTS COMPLETE THE 2-DOSE SERIES

Encourage them to book their second appointment at your office or a pharmacy by visiting ScheduleSHINGRIX.com.

Important Safety Information (cont'd)

- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see additional Important Safety Information for SHINGRIX throughout and full Prescribing Information, also available at SHINGRIXHCP.com.

References: **1.** Adult immunization standards. Centers for Disease Control and Prevention. Reviewed August 9, 2024. Accessed April 4, 2025. <https://www.cdc.gov/vaccines-adults/hcp/imz-standards/> **2.** Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2008;57(RR-5):1-30. **3.** Curran D, Matthews S, Boutry C, Lecrenier N, Cunningham AL, Schmader K. Natural history of herpes zoster in the placebo groups of three randomized phase III clinical trials. *Infect Dis Ther*. 2022;1(6):2265-2277. **4.** Shingles symptoms and complications. Centers for Disease Control and Prevention. Reviewed April 19, 2024. Accessed March 26, 2025. <https://www.cdc.gov/shingles/signs-symptoms/index.html> **5.** Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. *Open Forum Infect Dis*. 2020;7(1):1-8. **6.** Prescribing Information for SHINGRIX. **7.** Data on file. Study 113077 (NCT01165229). GSK Study Register. Study entry at: <https://www.gsk-studyregister.com/en/trial-details/?id=113077> **8.** Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. *J Med Virol*. 2003;70(suppl 1):S111-S118. **9.** Data on file, GSK. **10.** Wreschnig LA. Selected Health Provisions of the Inflation Reduction Act. Congressional Research Service. 2022;1-3. Accessed March 26, 2025. <https://www.congress.gov/crs-product/IF12203>

Trademarks are owned by or licensed to the GSK group of companies.

©2025 GSK or licensor.
PMUS-SGXLBN250008 May 2025
Produced in USA. 0002-0037-55

